Granulomatosis With Polyangiitis clinical trials

Explore recruiting granulomatosis with polyangiitis clinical trials.

Recruiting granulomatosis with polyangiitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Granulomatosis With Polyangiitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

eGPA and local inflammation within the ENT area; Impact of Mepolizumab treatment on the nasal microbiome and local and systemic immune response in eosinophilic granulomatosis with polyangitis (eGPA)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in EGPA- RACE-MATE

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

E-merge - Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

Italy, France, Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis.

Hungary, Denmark, Austria, Netherlands, Spain, Germany +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

France

Therapeutic use (Phase IV) EU CTIS Study details

Granulomatosis With Polyangiitis trials by city

Granulomatosis With Polyangiitis in Toronto Granulomatosis With Polyangiitis in Vancouver Granulomatosis With Polyangiitis in Montreal Granulomatosis With Polyangiitis in Calgary Granulomatosis With Polyangiitis in Edmonton Granulomatosis With Polyangiitis in Ottawa Granulomatosis With Polyangiitis in Winnipeg Granulomatosis With Polyangiitis in Quebec City Granulomatosis With Polyangiitis in Hamilton Granulomatosis With Polyangiitis in Kitchener Granulomatosis With Polyangiitis in London Granulomatosis With Polyangiitis in Halifax Granulomatosis With Polyangiitis in New York Granulomatosis With Polyangiitis in Los Angeles Granulomatosis With Polyangiitis in Chicago Granulomatosis With Polyangiitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease